Though biologics are a rapidly growing segment of the therapeutics space, many are not viable due to stability issues and short half-lives. Optimeos Life Sciences is developing nanoparticle-enabled technologies to advance patient care through more effective delivery of biologic therapeutics and is developing a proprietary encapsulation technology - licensed from Princeton - that readily enables a robust, and scalable synthesis of customizable nanoparticles. The self-assembled nature of these particles allows for encapsulation of biologic drugs with high yield and loading capacity. The nanoparticles are tunable in size, hydrophilicity, biodistribution, and surface chemistry. Successful demonstration has been made of encapsulation of fluorescent dyes, hydrophilic and hydrophobic drug substances, as well as inorganic materials within nanoparticles in a controlled manner. By using functionalized polymers, this encapsulation technology has created targeted nanoparticles for diagnostics and drug delivery. The targeting ligands on the functional polymer coatings range from sugars and peptides to monoclonal antibodies.
